Last updated: 2026-05-09

RxGrab Research

RxGrab publishes original research on prescription drug pricing reality. Our studies combine our first-party drug database with patent expiry data, wholesale pricing pulls, and crowdsourced retail pricing.

Published research

2026-05-09 ยท published

Brand-to-Generic Patent Cliff 2026: 50 Drugs, Post-Generic Price Decay, and the Stalled-Generic Cases That Never Got Cheaper

Audit of 50 drugs across patent expiry transitions cross-referenced with FDA Orange Book, USPTO patents, and ASPE pricing data. 45 have approved generics; 5 are pending the cliff (Ozempic, Wegovy, Jardiance, Eliquis, Xarelto). Cross-referenced with FTC Pay-for-Delay, CMS IRA, KFF Medicare Part D, and Mark Cuban Cost Plus public pricing. Editorial review pending PharmD partner.

Dataset: 50 drugs Primary sources: FDA Orange Book, Drugs@FDA, USPTO, CMS NADAC, FTC Pay-for-Delay, CBO IRA, GAO-19-498, IQVIA, RAND RR-A788-1, KFF, AAM, Mark Cuban Cost Plus

How we work

Every study ships with full methodology disclosure: dataset size, time range, exclusions, and source attribution. Surveys disclose sample size, recruitment platform, and demographic stratification. We publish raw data alongside the analysis under a Creative Commons Attribution 4.0 license so researchers, journalists, and operators can verify our claims and build on the work.

We do not run sponsored research, paid placements, or vendor-funded studies. Every study is funded directly by RxGrab as part of its independent editorial mission.

Press and citations

Journalists, researchers, and operators are welcome to cite our findings under CC-BY 4.0 with attribution. For interviews, exclusive embargoed access, or additional data cuts, contact [email protected].

Each study includes a press kit at its /press/ subpage with quotable findings, downloadable charts, and methodology summaries. Embargo requests honored when received at least 72 hours before scheduled publication.

All RxGrab research is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). Attribution required: link to the study URL or to rxgrab.com/research/.